Tokyo, Japan and Cambridge, UK, April 3, 2024 – Nxera Pharma (“Nxera” or the “Company”, TSE: 4565) – formerly known as Sosei Group or Sosei Heptares – today announced the appointment of Japanese pharmaceutical sector expert Patrick Branch for Japan. We are pleased to announce that we have been appointed as Business Development Manager. Asia Pacific region. Mr. Branch joins Nxera’s global business development team led by Dr. Marcus Messenger. He will be based in Nxera’s Tokyo office and will oversee disease area strategy, exploration and evaluation, and trading activities in Japan and the region.
Previously a partner and senior member of the global life sciences practice of LEK Consulting, a global strategy consulting firm, and co-chairman and managing director of LEK’s Japan office, Mr. Branch led LEK’s biopharmaceutical strategic consulting projects. He brings extensive industry experience through his leadership. His clients include medical technology, healthcare, and private equity. He has extensive management experience across hundreds of initiatives in Japan, Asia Pacific, and the United States on a variety of business-critical issues including growth strategy, business development and M&A, commercial strategy and operations, pricing and market access, and organizational design. I have given advice to the team.
Mr. Branch holds an MBA from INSEAD (Fontainebleau, France) and a Master of Public Health (MPH) from Columbia University Mailman School of Public Health (New York, USA). He also holds degrees from the University of Nottingham (Nottingham, UK) and SOAS, University of London (London, UK).
Chris Cargill, CEO and President of Nxera Pharma, commented: “We are pleased to welcome Patrick to the business development team at Nxera. This important appointment will enable us to develop and deliver life-changing medicines for patients in the large and rapidly growing Japan and Asia Pacific markets. , further demonstrates our commitment to driving and growing our Japan Comprehensive Pharmaceuticals business. Challenges and delays in new drug approvals in these markets represent a significant opportunity for our business, and we are positioned to take strategic advantage. I think we are in a good position.”
Patrick Branch, head of business development for Japan and Asia Pacific at Nxera Pharma, added: “Nxera is an emerging leader in Japan’s biopharmaceutical space and I am honored to join the company at such a pivotal time. I look forward to leveraging my experience to build on our existing strong foundation. , we look forward to helping drive business growth and new opportunities in Japan and the Asia-Pacific region. Our lean, go-to-market commercial model allows us to scale quickly and drive revenue. We are well-positioned to create significant value for our patients and our key stakeholders.”
-end-
About Nexera Pharma
Nxera Pharma (formerly Sosei Heptares) is a technology-enabled biopharmaceutical company pursuing new specialty medicines to improve the lives of patients with unmet needs in Japan and around the world.
In addition to several products commercialized in Japan, we drive an extensive pipeline of more than 30 active programs from discovery to late-stage clinical development, both internally and through partnerships with leading pharmaceutical and biotech companies. doing. This pipeline is focused on addressing key unmet needs in some of the fastest growing medical fields across neurology, gastrointestinal, immunology, metabolic disorders, and rare diseases, and is designed to drive the industry forward. Leveraging the power of our leading proprietary GPCR-targeted structure-based drug discovery. “NxWave”TM” platform to provide a sustainable source of top-class or first-in-class candidates.
Nxera employs over 350 talented people across major locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland), and Seoul (South Korea), and is listed on the Tokyo Stock Exchange (ticker : 4565).
For more information, please visit www.nxera.life.
LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma
inquiry:
Nxera Pharma – Media and Investor Relations
Kentaro Tahara, Vice President of Investor Relations and Corporate Strategy
Shinichiro Nishishita, Vice President of Investor Relations and Head of Regulatory Disclosure
Maya Bennison, Communications Manager
+81 (0)3 5210 3399 | +44 (0)1223 949390 | IR@Nxera.life
MEDiSTRAVA Consulting (for overseas media)
Mark Swallow, Fraser Hall, Erica Hollingsworth
+44 (0)203 928 6900 | Nxera@medistrava.com
Forward-looking statements
This press release contains forward-looking statements, including statements regarding product discovery, development and commercialization. A variety of risks could cause Nxera Pharma Group’s actual results to differ materially from those expressed or implied by the forward-looking statements. Failure to obtain patent protection for an invention. commercial restrictions imposed by patents owned or controlled by third parties; dependence on strategic alliance partners for the development and commercialization of products and services; difficulties or delays in obtaining regulatory approval to bring products and services to market resulting from development efforts; Significant capital is required to conduct research and development and expand commercialization activities. Competitor Product Initiatives. Because of these factors, prospective investors are cautioned not to rely on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
